A treatment for Non-Hodgkin’s Lymphoma gives patients a new option when current therapies fail.
Every year in the United States, nearly 60,000 people are told they have Non-Hodgkin’s Lymphoma.
Many patients become resistant to the available treatments.
Rhonda Waite and her best friend, Robin enjoys life's simple pleasures.
They both face cancer and rely on one another for humor and support.
Rhonda has been fighting slow growing Non-Hodgkin’s Lymphoma for 15 years.
When she grew resistant to the drug Rituximab, the gold standard for her cancer, she needed another option.
She joined a clinical trial with a drug called Bendamustine.
Jonathan Friedberg, M.D. at the University of Rochester said, "More than 70% of them had good responses to the treatment."
About 35% even went into remission.